Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 14/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 7/20 | 0.41 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.40 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.38 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.38 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | GBA1 | P04062 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1776461 | 0.88 | TLR7 (0.50) | TLR7TLR8 | |
| SCHEMBL4790367 | 0.84 | ACP1 (0.39) | HTR4 | |
| SCHEMBL1232410 | 0.82 | TLR7 (0.51) | TLR7TLR8 | |
| SCHEMBL12667231 | 0.82 | TLR7 (0.42) | TLR7TLR8HTR4PRKD3PRKD1 | |
| SCHEMBL1776500 | 0.79 | TLR7 (0.49) | TLR7TLR8 | |
| SCHEMBL1232558 | 0.78 | TLR7 (0.46) | TLR7TLR8 | |
| SCHEMBL1233234 | 0.78 | TLR7 (0.48) | TLR7TLR8 | |
| SCHEMBL1233785 | 0.78 | TLR7 (0.53) | TLR7TLR8 | |
| SCHEMBL1232718 | 0.78 | TLR7 (0.47) | TLR7TLR8 | |
| SCHEMBL1233720 | 0.78 | TLR7 (0.40) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10472420-B2 | Immune response modifier conjugates | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2019-11-12 | — | — | US | disclosed |
| EP-3085373-A1 | IMMUNE RESPONSE MODIFIER CONJUGATES | 3M Innovative Properties Company (US) | 2016-10-26 | — | — | EP | disclosed |
| US-20150141625-A1 | IMMUNE RESPONSE MODIFIER CONJUGATES | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2015-05-21 | — | — | US | disclosed |
| US-8951528-B2 | Immune response modifier conjugates | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2015-02-10 | — | — | US | disclosed |
| US-20090035323-A1 | IMMUNE RESPONSE MODIFIER CONJUGATES | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141625-A1 | IMMUNE RESPONSE MODIFIER CONJUGATES | IFNG, CD74, MYD88 | TLR7 92/4885TLR8 71/4885HTR4 4292/4885 |
| US-20090035323-A1 | IMMUNE RESPONSE MODIFIER CONJUGATES | IFNG, CD74, MYD88 | TLR7 92/4885TLR8 71/4885HTR4 4292/4885 |
| US-10472420-B2 | Immune response modifier conjugates | IFNG, CD74, MYD88 | TLR7 92/4885TLR8 71/4885HTR4 4292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.